Treatment Strategies: From Corticosteroids to Rituximab
At a Glance
Modern treatment for Pemphigus Foliaceus has shifted from long-term steroids to targeted therapies like rituximab. For moderate to severe cases, rituximab acts as a first-line treatment to suppress the immune attack, allowing the skin to heal while safely reducing steroid dependence.
In the past, a diagnosis of Pemphigus Foliaceus (PF) meant many years of high-dose steroids. While steroids saved lives, the side effects were often as challenging as the disease itself. Today, international guidelines from organizations like the European Dermatology Forum (EDF) and the British Association of Dermatologists (BAD) have shifted the focus toward “steroid-sparing” strategies that aim to heal your skin while protecting your overall health.
The Foundation: Systemic Corticosteroids
For most patients, treatment begins with systemic corticosteroids (such as prednisone). These are powerful anti-inflammatory drugs that work quickly to “turn off” the immune attack on your skin [1][2].
However, steroids are like a heavy hammer: they are effective, but they affect the whole body. Because of this, doctors now use them as a “bridge” to get the disease under control while other, more targeted medications take over [1].
The Modern Standard: Rituximab
One of the most significant changes in PF care is the use of rituximab. Once used only as a “last resort,” it is now recommended as a first-line therapy for moderate-to-severe PF [3][4].
- How it Works: Rituximab is a monoclonal antibody that targets a specific protein (CD20) on your B-cells [5]. Think of B-cells as the “factories” that produce the harmful autoantibodies attacking your skin glue. Rituximab essentially shuts down these factories for several months [6].
- How it is Administered: Rituximab is not a pill. It is administered as an intravenous (IV) infusion in a clinic or hospital setting. A typical schedule involves two initial infusions given two weeks apart. Because there is a risk of immediate infusion reactions, the medical staff will monitor you closely and likely give you pre-medications (like antihistamines and acetaminophen) to keep you comfortable.
- The Benefit and Timeline: By removing the source of the attack, rituximab allows the skin to heal and allows patients to reduce their steroid dose much faster [7]. It usually takes several weeks to a few months for rituximab to fully stop the disease process and for skin to stop flaking [8].
Choosing Your Treatment Path
Your medical team will likely choose a treatment path based on the severity of your symptoms. This is often measured using a tool called the Pemphigus Disease Area Index (PDAI), which scores the number and size of your skin lesions [7].
| Severity | Typical Treatment Approach |
|---|---|
| Mild | Often managed with high-potency topical steroids (creams) or low-dose oral steroids. Some doctors may use dapsone as an oral option [9][10]. |
| Moderate to Severe | Guidelines recommend starting rituximab early, combined with a tapering course of oral steroids [3][4]. |
| Recalcitrant (Difficult to Treat) | If the disease doesn’t respond to first-line options, doctors may add other “steroid-sparing” immunosuppressants like azathioprine or mycophenolate mofetil [11][12]. |
Other Key Players: Steroid-Sparing Agents
If rituximab is not an option for you, or if your case is particularly stubborn, your doctor may use other medications to help lower your steroid dose:
- Azathioprine: A traditional immunosuppressant that helps maintain remission over the long term [13]. It can cause stomach upset and requires regular blood tests to monitor your liver and blood counts.
- Mycophenolate Mofetil: Another option that helps quiet the immune system, though it may take several weeks to begin working [12]. Gastrointestinal side effects like diarrhea are common.
- Dapsone: An older medication that can be very effective for milder or “crusty” localized forms of PF [10].
The goal of modern PF treatment is not just clear skin, but a clear life. By using targeted therapies like rituximab early, the “steroid hammer” can be used more sparingly, leading to a safer path toward long-term remission.
Common questions in this guide
What is the most effective treatment for moderate to severe Pemphigus Foliaceus?
How does a doctor decide which treatment is right for me?
What are steroid-sparing agents?
How is rituximab administered for Pemphigus Foliaceus?
How is mild Pemphigus Foliaceus treated?
Questions to Ask Your Doctor
Curated prompts to bring to your next appointment.
- 1.Based on my Pemphigus Disease Area Index (PDAI) score, do I have mild, moderate, or severe PF?
- 2.Am I a candidate for rituximab as a first-line treatment to help reduce my total steroid dose?
- 3.Which 'steroid-sparing' agent (like azathioprine or mycophenolate) do you recommend for my specific health history?
- 4.What are the most common daily side effects I should watch out for with these oral medications?
- 5.What tests (like G6PD or TPMT enzyme levels) do I need before starting these medications?
- 6.What is the planned timeline for tapering my prednisone once my skin begins to heal?
Questions For You
Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.
References
References (13)
- 1
Clinicodemographic characteristics of pemphigus foliaceus: retrospective analysis of clinic-based data for 103 patients in a nonendemic location.
De D, Sharma A, Hanumanthu V, et al.
Clinical and experimental dermatology 2026; (51(5)):840-845 doi:10.1093/ced/llaf408.
PMID: 40931562 - 2
Fogo selvagem: endemic pemphigus foliaceus.
Hans-Filho G, Aoki V, Bittner NRH, Bittner GC
Anais brasileiros de dermatologia 2018; (93(5)):638-650 doi:10.1590/abd1806-4841.20188235.
PMID: 30156612 - 3
Efficacy and Safety of Rituximab in Pemphigus Foliaceus: A Systematic Review and Meta-analysis.
Kieffer C, Hebert V, Joly P, Tedbirt B
Dermatology and therapy 2026; doi:10.1007/s13555-026-01811-0.
PMID: 42390708 - 4
Ocrelizumab, an alternative to rituximab in refractory pemphigus vulgaris management.
de-la-Rosa-Fernández E, Loizate-Sarrionandia I, González-Rodríguez J, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV 2023; (37(9)):e1104-e1106 doi:10.1111/jdv.19133.
PMID: 37102356 - 5
Anti-CD20 monoclonal antibodies in Systemic Lupus Erythematosus.
Shah K, Cragg M, Leandro M, Reddy V
Biologicals : journal of the International Association of Biological Standardization 2021; (69()):1-14 doi:10.1016/j.biologicals.2020.11.002.
PMID: 33288390 - 6
Emerging Treatments in Pemphigus: Is Healing an Achievable Goal?
Horváth B, Hiel MAJ, Strandmoe AL, Meijer JM
American journal of clinical dermatology 2026; (27(2)):317-327 doi:10.1007/s40257-025-01002-1.
PMID: 41460304 - 7
B-cell targeted therapies in pemphigus.
Maglie R, Antiga E, Payne AS
Italian journal of dermatology and venereology 2021; (156(2)):161-173 doi:10.23736/S2784-8671.20.06694-8.
PMID: 33016669 - 8
Clinical correlation of anti-desmoglein antibody dynamics in pemphigus treated with rituximab.
Naidu V, Jain HA, Yalcinkaya A, et al.
Frontiers in immunology 2025; (16()):1713987 doi:10.3389/fimmu.2025.1713987.
PMID: 41459496 - 9
Red crusty plaques in a young man.
Farsi M, Johnson CM, Segars K, Rhim J
Dermatology online journal 2023; (29(5)) doi:10.5070/D329562411.
PMID: 38478647 - 10
Localized Pemphigus Foliaceus: Diverse Presentations, Treatment, and Review of the Literature.
Kunadia A, Moschella S, McLemore J, Sami N
Indian journal of dermatology 2023; (68(1)):123 doi:10.4103/ijd.ijd_324_22.
PMID: 37151255 - 11
A Case of Recurrent Pemphigus Foliaceus Following Noncompliance to Medication.
Ali M, Ahmad MH, Imran A, et al.
Clinical case reports 2024; (12(11)):e9622 doi:10.1002/ccr3.9622.
PMID: 39582723 - 12
A retrospective evaluation of the steroid sparing effects of oral mycophenolate mofetil (MMF) as an adjunct immunosuppressant for the treatment of canine pemphigus foliaceus.
Putra A, Austel M, Banovic F
Veterinary dermatology 2022; (33(1)):77-e24 doi:10.1111/vde.13028.
PMID: 34697841 - 13
Epidemiology and Factors Associated with Remission of Pemphigus Vulgaris and Foliaceus in Singapore.
Cai SC, Zhao X, Tang MB, Lim YL
Annals of the Academy of Medicine, Singapore 2020; (49(6)):367-376.
PMID: 32712634
This page provides information on Pemphigus Foliaceus treatments for educational purposes only. Always consult your dermatologist or healthcare provider before making changes to your medication or treatment plan.
Get notified when new evidence is published on Pemphigus foliaceus.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.